A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: [14C]-LY3556050
- Registration Number
- NCT06052462
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to evaluate how much of the study drug (LY3556050), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 58 days including the screening period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 7
- Male participants who are overtly healthy as determined by medical evaluation
- Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive
- Males who agree to use highly effective or effective methods of contraception
- Have known allergies to LY3556050, related compounds, or any components of the formulation of LY3556050, or history of significant atopy
- Have clinically significant abnormal BP and/or pulse rate as determined by the investigator
- Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description [14C]-LY3556050 [14C]-LY3556050 Single dose of \[¹⁴C\]-LY3556050 administered orally
- Primary Outcome Measures
Name Time Method Fecal Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered Predose up to Day 21 post dose Fecal Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered Predose up to Day 21 post dose Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
- Secondary Outcome Measures
Name Time Method PK: AUC(0-tlast) of Total Radioactivity in Plasma and Blood Predose up to Day 21 post dose PK: AUC(0-tlast) of Total Radioactivity in Plasma and Blood
PK: Maximum Concentration (Cmax) of LY3556050 in Plasma Predose up to Day 21 post dose PK: Cmax of LY3556050 in Plasma
PK: Area Under the Curve Concentration Versus Time Curve From zero to Infinity (AUC [0-∞]) of LY3556050 in Plasma Predose up to Day 21 post dose PK: AUC (0-∞) of LY3556050 in Plasma
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable) Predose up to Day 7 post dose Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)
Pharmacokinetics (PK): Area Under the Curve Concentration Versus Time Curve From Time zero to Last Time Point (AUC[0-tlast]) of LY3556050 in Plasma Predose up to Day 21 post dose PK: AUC(0-tlast) of LY3556050 in Plasma
PK: AUC (0-∞) of Total Radioactivity in Plasma and Blood Predose up to Day 21 post dose PK: AUC (0-∞) of Total Radioactivity in Plasma and Blood
PK: Cmax of Total Radioactivity in Plasma and Blood Predose up to Day 21 post dose PK: Cmax of Total Radioactivity in Plasma and Blood
Total Number of Metabolites of LY3556050 Predose up to Day 7 post dose Total Number of Metabolites of LY3556050
Trial Locations
- Locations (1)
LabCorp CRU, Inc.
🇺🇸Madison, Wisconsin, United States